FDA and Medicare Regulation—Their Role And What Will Happen In the Future – Part Two of a Two Part Post
Will the Centers for Medicare & Medicaid Services (CMS) be able to optimize patient care with regard to both on-label and off-label drugs? CMS', at this time, has not shown itself to be either in [...]
FDA and Medicare Regulation—Their Role And What Will Happen In the Future – Part One of a Two Part Post
Historically, I have been critical of the FDA, especially around the delay of the approval of Provenge. Now, it is time to take a look at the FDA and what I believe the future will [...]
No Good Treatment for Men with Chemotherapy Induced Neuropathy
One of the common side effects reported from chemotherapy with Taxotere is neuropathy. In the trial used to receive FDA approval, TAX 327 which had 332 patients. In that trial the following percentage of men [...]
Denosumab (Xgeva) Benefits Greatest in Men with Rapid PSA Kinetics
Denosumab (Xgeva), the recently approved and only therapy that prolongs bone metastasis-free survival in men with non-metastatic castrate-resistant prostate cancer (CRPC) who are at high risk for the spread of prostate cancer metastasis to bone [...]
Can Photo Dynamic Therapy Be On The Horizon?
Over the years there has been discussion about using Photo Dynamic Therapy to destroy internal tumors, including prostate cancer tumors. Until now it has only been a hope since there is no way to monitor [...]
More From ASCO – Too Many Patients with Advanced Prostate Cancer Do Not Get Required Treatment
Abstract No:101 at the recent ASCO Conference It is sad, but it is true, a subset of men presenting with advanced prostate cancer never receive proper therapy. This can be attributed to a variety of [...]